Skip to Content
You are currently on the new version of our website. Access the old version .
  • Article
  • Open Access

22 March 2024

11 Pages

Evaluating Community-Based Intrathecal Baclofen Therapy: Effectiveness, Safety, and Feasibility

,
,
,
and
1
Ambulatory Care Clinic, Care4homecare, Rond Deel 12, 5531 AH Bladel, The Netherlands
2
Center for Pain Medicine, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
*
Author to whom correspondence should be addressed.
This article belongs to the Section Clinical Neurology

Abstract

Background: Intrathecal baclofen (ITB) is used for the treatment of intractable spasticity. The burden of traveling for ITB screening and aftercare is problematic for nursing home residents with severe spasticity and seems to result in undertreatment of spasticity. The aim of this study is to evaluate the effectiveness, safety, and feasibility of ITB for nursing home residents treated in their home, describing the selection phase, the initial trial of ITB, and aftercare up to 3 months after implantation of an ITB pump. Methods: This retrospective database study included immobile, adult nursing home residents with severe spasticity, referred to an Ambulatory Care Clinic between 2016 and 2021. When eligible, an ITB trial was performed by ITB experts in the nursing home. If a permanent pump was implanted, dose titration and aftercare were performed on location. Results: A total of 102 patients were referred; 80 underwent an ITB trial on location, and 94% improved significantly on the Modified Ashworth Scale and clonus scale pre-ITB trial versus post-ITB trial, as well as at 3 months post-implantation. There was a low incidence of adverse events, mostly procedure- and drug-related. Conclusions: This study indicates that selection, testing, and aftercare for ITB on location is effective and safe.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.